Inflammatory corneal neovascularization: Etiopathogenesis

Seminars in Ophthalmology

Volumn 26, Issue 4-5, 2011, Pages 235-245

  Clements, John L ^a   Dana, Reza ^a  

^a MASSACHUSETTS EYE AND EAR INFIRMARY   (United States)

Author keywords

Angiogenesis; Cornea; Corneal transplantation; Hemangiogenesis; Inflammation

Indexed keywords

ALKALI; ANGIOGENESIS INHIBITOR; ANGIOSTATIN; ANTIBODY; CYTOKINE; ENDOSTATIN; FIBROBLAST GROWTH FACTOR; INTEGRIN; INTERLEUKIN 1ALPHA; MATRIX METALLOPROTEINASE; NYLON; PIGMENT EPITHELIUM DERIVED FACTOR; SUTURE MATERIAL; TUMOR NECROSIS FACTOR ALPHA; VASCULOTROPIN; VASCULOTROPIN RECEPTOR 1; VASCULOTROPIN RECEPTOR 3;

ALKALI INJURY; ANGIOGENESIS; BACTERIAL KERATITIS; CHEMICAL INJURY; CONTACT LENS; CORNEA; CORNEA NEOVASCULARIZATION; DISEASE ASSOCIATION; HERPES SIMPLEX KERATITIS; HUMAN; INFLAMMATORY CORNEAL NEOVASCULARIZATION; KERATITIS; LITERATURE; MACROPHAGE; NONHUMAN; PATHOGENESIS; PENETRATING KERATOPLASTY; PRIORITY JOURNAL; REVIEW;

ANGIOGENESIS INHIBITORS; ANGIOGENIC PROTEINS; ANIMALS; CORNEA; CORNEAL NEOVASCULARIZATION; HUMANS;

EID: 80053530219     PISSN: 08820538     EISSN: 17445205     Source Type: Journal    
DOI: 10.3109/08820538.2011.588652     Document Type: Review

References (118)

1. Liesegang TJ. Epidemiology of ocular herpes simplex. Natural history in Rochester, Minn, 1950 through 1982. Arch Ophthalmol. Aug 1989;107(8):1160-1165
2. Resnikoff S, Pascolini D, Etya'ale D, et al. Global data on visual impairment in the year 2002. Bull World Health Organ. Nov 2004;82(11):844-851
3. Lee P, Wang CC, Adamis AP. Ocular neovascularization: An epidemiologic review. Surv Ophthalmol. Nov-Dec 1998;43(3):245-269 (Pubitemid 28558273)
4. Carmeliet P. Angiogenesis in health and disease. Nat Med. Jun 2003;9(6):653-660 (Pubitemid 36749213)
5. Penn JS, Madan A, Caldwell RB, Bartoli M, Caldwell RW, Hartnett ME. Vascular endothelial growth factor in eye disease. Prog Retin Eye Res. Jul 2008;27(4):331-371
6. Ellenberg D, Azar DT, Hallak JA, et al. Novel aspects of corneal angiogenic and lymphangiogenic privilege. Prog Retin Eye Res. May 2010;29(3):208-248
7. Corada M, Zanetta L, Orsenigo F, et al. A monoclonal antibody to vascular endothelial-cadherin inhibits tumor angiogenesis without side effects on endothelial permeability. Blood. Aug 1 2002;100(3):905-911 (Pubitemid 34832616)
8. Luttun A, Dewerchin M, Collen D, Carmeliet P. The role of proteinases in angiogenesis, heart development, restenosis, atherosclerosis, myocardial ischemia, and stroke: Insights from genetic studies. Curr Atheroscler Rep. Sep 2000;2(5):407-416
9. Bajou K, Noel A, Gerard RD, et al. Absence of host plasminogen activator inhibitor 1 prevents cancer invasion and vascularization. Nat Med. Aug 1998;4(8):923-928 (Pubitemid 28364031)
10. Pepper MS. Extracellular proteolysis and angiogenesis. Thromb Haemost. Jul 2001;86(1):346-355 (Pubitemid 32663965)
11. Jackson C. Matrix metalloproteinases and angiogenesis. Curr Opin Nephrol Hypertens. May 2002;11(3):295-299 (Pubitemid 34496777)
12. Jain RK. Molecular regulation of vessel maturation. Nat Med. Jun 2003;9(6):685-693 (Pubitemid 36749217)
13. Dastjerdi MH, Al-Arfaj KM, Nallasamy N, et al. Topical bevacizumab in the treatment of corneal neovascularization: Results of a prospective, open-label, noncomparative study. Arch Ophthalmol. Apr 2009;127(4):381-389
14. Bock F, Konig Y, Kruse F, Baier M, Cursiefen C. Bevacizumab (Avastin) eye drops inhibit corneal neovascularization. Graefes Arch Clin Exp Ophthalmol. Feb 2008;246(2):281-284 (Pubitemid 351149633)
15. Carmeliet P. VEGF as a key mediator of angiogenesis in cancer. Oncology. 2005;69 Suppl 3:4-10 (Pubitemid 41680947)
16. Cursiefen C, Chen L, Borges LP, et al. VEGF-A stimulates lymphangiogenesis and hemangiogenesis in inflammatory neovascularization via macrophage recruitment. J Clin Invest. Apr 2004;113(7):1040-1050 (Pubitemid 38544126)
17. Cao Y, Linden P, Farnebo J, et al. Vascular endothelial growth factor C induces angiogenesis in vivo. Proc Natl Acad Sci U S A. Nov 24 1998;95(24):14389-14394 (Pubitemid 28549377)
18. Azar DT. Corneal angiogenic privilege: Angiogenic and antiangiogenic factors in corneal avascularity, vasculogenesis, and wound healing (an American Ophthalmological Society thesis). Trans Am Ophthalmol Soc. 2006;104:264-302 (Pubitemid 46495064)
19. Amano S, Rohan R, Kuroki M, Tolentino M, Adamis AP. Requirement for vascular endothelial growth factor in wound- and inflammation-related corneal neovascularization. Invest Ophthalmol Vis Sci. Jan 1998;39(1):18-22 (Pubitemid 28040457)
20. Kvanta A, Sarman S, Fagerholm P, Seregard S, Steen B. Expression of matrix metalloproteinase-2 (MMP-2) and vascular endothelial growth factor (VEGF) in inflammationassociated corneal neovascularization. Exp Eye Res. Apr 2000;70(4):419-428 (Pubitemid 30658885)
21. Mastyugin V, Mosaed S, Bonazzi A, Dunn MW, Schwartzman ML. Corneal epithelial VEGF and cytochrome P450 4B1 expression in a rabbit model of closed eye contact lens wear. Curr Eye Res. Jul 2001;23(1):1-10 (Pubitemid 34494008)
22. Zheng M, Deshpande S, Lee S, Ferrara N, Rouse BT. Contribution of vascular endothelial growth factor in the neovascularization process during the pathogenesis of herpetic stromal keratitis. J Virol. Oct 2001;75(20):9828-9835 (Pubitemid 32900118)
23. Witmer AN, Vrensen GF, Van Noorden CJ, Schlingemann RO. Vascular endothelial growth factors and angiogenesis in eye disease. Prog Retin Eye Res. Jan 2003;22(1):1-29 (Pubitemid 36207453)
24. Tammela T, Zarkada G, Wallgard E, et al. Blocking VEGFR-3 suppresses angiogenic sprouting and vascular network formation. Nature. Jul 31 2008;454(7204):656-660
25. Chung ES, Chauhan SK, Jin Y, et al. Contribution of macrophages to angiogenesis induced by vascular endothelial growth factor receptor-3-specific ligands. Am J Pathol. Nov 2009;175(5):1984-1992
26. Chen L, Hamrah P, Cursiefen C, et al. Vascular endothelial growth factor receptor-3 mediates induction of corneal alloimmunity. Nat Med. Aug 2004;10(8):813-815 (Pubitemid 39070853)
27. Yang ZF, Poon RT, Luo Y, et al. Up-regulation of vascular endothelial growth factor (VEGF) in small-for-size liver grafts enhances macrophage activities through VEGF receptor 2-dependent pathway. J Immunol. Aug 15 2004;173(4):2507-2515 (Pubitemid 39063109)
28. Sawano A, Iwai S, Sakurai Y, et al. Flt-1, vascular endothelial growth factor receptor 1, is a novel cell surface marker for the lineage of monocyte-macrophages in humans. Blood. Feb 1 2001;97(3):785-791 (Pubitemid 32113414)
29. Woessner JF, Jr. The family of matrix metalloproteinases. Ann N Y Acad Sci. Sep 6 1994;732:11-21
30. Mignatti P, Rifkin DB. Plasminogen activators and matrix metalloproteinases in angiogenesis. Enzyme Protein. 1996;49(1-3):117-137 (Pubitemid 26181742)
31. van Hinsbergh VW, Engelse M.A., Quax PH. Pericellular proteases in angiogenesis and vasculogenesis. Arterioscler Thromb Vasc Biol. Apr 2006;26(4):716-728 (Pubitemid 43732143)
32. Kato T, Kure T, Chang JH, et al. Diminished corneal angiogenesis in gelatinase A-deficient mice. FEBS Lett. Nov 16 2001;508(2):187-190 (Pubitemid 33079244)
33. Shi W, Liu J, Li M, Gao H, Wang T. Expression of MMP, HPSE, and FAP in stroma promoted corneal neovascularization induced by different etiological factors. Curr Eye Res. Nov 2010;35(11):967-977
34. Azar DT, Casanova FH, Mimura T, et al. Corneal epithelial MT1-MMP inhibits vascular endothelial cell proliferation and migration. Cornea. Mar 2010;29(3):321-330
35. Maciag T, Mehlman T, Friesel R, Schreiber AB. Heparin binds endothelial cell growth factor, the principal endothelial cell mitogen in bovine brain. Science. Aug 31 1984;225(4665):932-935 (Pubitemid 14064174)
36. Itoh N, Ornitz DM. Evolution of the Fgf and Fgfr gene families. Trends Genet. Nov 2004;20(11):563-569 (Pubitemid 39314564)
37. Presta M, Dell'Era P, Mitola S, Moroni E, Ronca R, Rusnati M. Fibroblast growth factor/fibroblast growth factor receptor system in angiogenesis. Cytokine Growth Factor Rev. Apr 2005;16(2):159-178 (Pubitemid 40616114)
38. Rusnati M, Presta M. Fibroblast growth factors/fibroblast growth factor receptors as targets for the development of anti-angiogenesis strategies. Curr Pharm Des. 2007;13(20):2025-2044 (Pubitemid 47040487)
39. Cenni E, Perut F, Granchi D, et al. Inhibition of angiogenesis via FGF-2 blockage in primitive and bone metastatic renal cell carcinoma. Anticancer Res. Jan-Feb 2007;27(1A):315-319
40. Javerzat S, Auguste P, Bikfalvi A. The role of fibroblast growth factors in vascular development. Trends Mol Med. Oct 2002;8(10):483-489
41. Presta M, Maier JA, Rusnati M, Ragnotti G. Basic fibroblast growth factor is released from endothelial extracellular matrix in a biologically active form. J Cell Physiol. Jul 1989;140(1):68-74 (Pubitemid 19180158)
42. Gualandris A, Rusnati M, Belleri M, et al. Basic fibroblast growth factor overexpression in endothelial cells: An autocrine mechanism for angiogenesis and angioproliferative diseases. Cell Growth Differ. Feb 1996;7(2):147-160 (Pubitemid 26049823)
43. Chung ES, Saban DR, Chauhan SK, Dana R. Regulation of blood vessel versus lymphatic vessel growth in the cornea. Invest Ophthalmol Vis Sci. Apr 2009;50(4):1613-1618
44. Tille JC, Wood J, Mandriota SJ, et al. Vascular endothelial growth factor (VEGF) receptor-2 antagonists inhibit VEGF- and basic fibroblast growth factor-induced angiogenesis in vivo and in vitro. J Pharmacol Exp Ther. Dec 2001;299(3):1073-1085 (Pubitemid 33104979)
45. Auguste P, Gursel DB, Lemiere S, et al. Inhibition of fibroblast growth factor/fibroblast growth factor receptor activity in glioma cells impedes tumor growth by both angiogenesisdependent and -independent mechanisms. Cancer Res. Feb 15 2001;61(4):1717-1726 (Pubitemid 34292610)
46. Vlahakis NE, Young BA, Atakilit A, et al. Integrin alpha9- beta1 directly binds to vascular endothelial growth factor (VEGF)-A and contributes to VEGF-A-induced angiogenesis. J Biol Chem. May 18 2007;282(20):15187-15196 (Pubitemid 47093385)
47. Hemler ME. VLA proteins in the integrin family: Structures, functions, and their role on leukocytes. Annu Rev Immunol. 1990;8:365-400 (Pubitemid 20135632)
48. Chen L, Huq S, Gardner H, de Fougerolles AR, Barabino S, Dana MR. Very late antigen 1 blockade markedly promotes survival of corneal allografts. Arch Ophthalmol. Jun 2007;125(6):783-788 (Pubitemid 46919739)
49. Senger DR, Perruzzi CA, Streit M, Koteliansky VE, de Fougerolles AR, Detmar M. The alpha(1)beta(1) and alpha(2)beta(1) integrins provide critical support for vascular endothelial growth factor signaling, endothelial cell migration, and tumor angiogenesis. Am J Pathol. Jan 2002;160(1):195-204 (Pubitemid 34052280)
50. Dinarello CA. Biologic basis for interleukin-1 in disease. Blood. Mar 15 1996;87(6):2095-2147 (Pubitemid 26086851)
51. Dana MR, Zhu SN, Yamada J. Topical modulation of interleukin- 1 activity in corneal neovascularization. Cornea. Jul 1998;17(4):403-409 (Pubitemid 28307507)
52. Nakao S, Hata Y, Miura M, et al. Dexamethasone inhibits interleukin-1beta-induced corneal neovascularization: Role of nuclear factor-kappaB-activated stromal cells in inflammatory angiogenesis. Am J Pathol. Sep 2007;171(3):1058-1065 (Pubitemid 47441002)
53. Banerjee K, Biswas PS, Kim B, Lee S, Rouse BT. CXCR2-/- mice show enhanced susceptibility to herpetic stromal keratitis: A role for IL-6-induced neovascularization. J Immunol. Jan 15 2004;172(2):1237-1245 (Pubitemid 38113787)
54. Ebrahem Q, Minamoto A, Hoppe G, Anand-Apte B, Sears JE. Triamcinolone acetonide inhibits IL-6- and VEGF-induced angiogenesis downstream of the IL-6 and VEGF receptors. Invest Ophthalmol Vis Sci. Nov 2006;47(11):4935-4941 (Pubitemid 46586396)
55. Lim P, Fuchsluger TA, Jurkunas UV. Limbal stem cell deficiency and corneal neovascularization. Semin Ophthalmol. May-Jun 2009;24(3):139-148
56. Cursiefen C, Chen L, Saint-Geniez M, et al. Nonvascular VEGF receptor 3 expression by corneal epithelium maintains avascularity and vision. Proc Natl Acad Sci U S A. Jul 25 2006;103(30):11405-11410 (Pubitemid 44156530)
57. Ambati BK, Nozaki M, Singh N, et al. Corneal avascularity is due to soluble VEGF receptor-1. Nature. Oct 26 2006;443(7114):993-997 (Pubitemid 44646176)
58. Harper JY, Samuelson DA, Reep RL. Corneal vascularization in the Florida manatee (Trichechus manatus latirostris) and three-dimensional reconstruction of vessels. Vet Ophthalmol. Mar-Apr 2005;8(2):89-99 (Pubitemid 40446041)
59. Karakousis PC, John SK, Behling KC, et al. Localization of pigment epithelium derived factor (PEDF) in developing and adult human ocular tissues. Mol Vis. Jun 30 2001;7:154-163 (Pubitemid 36153665)
60. Dawson DW, Volpert OV, Gillis P, et al. Pigment epitheliumderived factor: A potent inhibitor of angiogenesis. Science. Jul 9 1999;285(5425):245-248 (Pubitemid 29329995)
61. Meyer C, Notari L, Becerra SP. Mapping the type I collagen- binding site on pigment epithelium-derived factor. Implications for its antiangiogenic activity. J Biol Chem. Nov 22 2002;277(47):45400-45407 (Pubitemid 36159148)
62. Sheikpranbabu S, Haribalaganesh R, Banumathi E, Sirishkumar N, Lee KJ, Gurunathan S. Pigment epitheliumderived factor inhibits advanced glycation end-productinduced angiogenesis and stimulates apoptosis in retinal endothelial cells. Life Sci. Nov 18 2009;85(21-22):719-731
63. Kuo CN, Yang LC, Yang CT, et al. Inhibition of corneal neovascularization with plasmid pigment epithelium-derived factor (p-PEDF) delivered by synthetic amphiphile INTeraction-18 (SAINT-18) vector in an experimental model of rat corneal angiogenesis. Exp Eye Res. Nov 2009;89(5):678-685
64. Jin J, Ma JX, Guan M, Yao K. Inhibition of chemical cautery- induced corneal neovascularization by topical pigment epithelium-derived factor eyedrops. Cornea. Sep 2010;29(9):1055-1061
65. O'Reilly MS, Holmgren L, Shing Y, et al. Angiostatin: A novel angiogenesis inhibitor that mediates the suppression of metastases by a Lewis lung carcinoma. Cell. Oct 21 1994;79(2):315-328 (Pubitemid 24324921)
66. O'Reilly MS, Wiederschain D, Stetler-Stevenson WG, Folkman J, Moses M.A., Regulation of angiostatin production by matrix metalloproteinase-2 in a model of concomitant resistance. J Biol Chem. Oct 8 1999;274(41):29568-29571
67. Albini A, Brigati C, Ventura A, et al. Angiostatin anti-angiogenesis requires IL-12: The innate immune system as a key target. J Transl Med. 2009;7:5
68. Griscelli F, Li H, Bennaceur-Griscelli A, et al. Angiostatin gene transfer: inhibition of tumor growth in vivo by blockage of endothelial cell proliferation associated with a mitosis arrest. Proc Natl Acad Sci U S A. May 26 1998;95(11):6367-6372 (Pubitemid 28249018)
69. Moser TL, Stack MS, Asplin I, et al. Angiostatin binds ATP synthase on the surface of human endothelial cells. Proc Natl Acad Sci U S A. Mar 16 1999;96(6):2811-2816 (Pubitemid 29148800)
70. Pluskota E, Soloviev DA, Szpak D, Weber C, Plow EF. Neutrophil apoptosis: Selective regulation by different ligands of integrin alphaMbeta2. J Immunol. Sep 1 2008;181(5):3609-3619
71. Chavakis T, Athanasopoulos A, Rhee JS, et al. Angiostatin is a novel anti-inflammatory factor by inhibiting leukocyte recruitment. Blood. Feb 1 2005;105(3):1036-1043 (Pubitemid 40170873)
72. Lee S, Zheng M, Deshpande S, Eo SK, Hamilton TA, Rouse BT. IL-12 suppresses the expression of ocular immunoinflammatory lesions by effects on angiogenesis. J Leukoc Biol. Mar 2002;71(3):469-476
73. O'Reilly MS, Boehm T, Shing Y, et al. Endostatin: An endogenous inhibitor of angiogenesis and tumor growth. Cell. Jan 24 1997;88(2):277-285 (Pubitemid 28015876)
74. Kim YM, Hwang S, Pyun BJ, et al. Endostatin blocks vascular endothelial growth factor-mediated signaling via direct interaction with KDR/Flk-1. J Biol Chem. Aug 2 2002;277(31):27872-27879 (Pubitemid 34966733)
75. Eriksson K, Magnusson P, Dixelius J, Claesson-Welsh L, Cross MJ. Angiostatin and endostatin inhibit endothelial cell migration in response to FGF and VEGF without interfering with specific intracellular signal transduction pathways. FEBS Lett. Feb 11 2003;536(1-3):19-24 (Pubitemid 36206399)
76. Sotozono C, He J, Matsumoto Y, Kita M, Imanishi J, Kinoshita S. Cytokine expression in the alkali-burned cornea. Curr Eye Res. Jul 1997;16(7):670-676 (Pubitemid 27322719)
77. Wilson SE, Mohan RR, Ambrosio R, Jr., Hong J, Lee J. The corneal wound healing response: Cytokine-mediated interaction of the epithelium, stroma, and inflammatory cells. Prog Retin Eye Res. Sep 2001;20(5):625-637 (Pubitemid 32695343)
78. Liesegang TJ, Melton LJ, 3rd, Daly PJ, Ilstrup DM. Epidemiology of ocular herpes simplex. Incidence in Rochester, Minn, 1950 through 1982. Arch Ophthalmol. Aug 1989;107(8):1155-1159 (Pubitemid 19195642)
79. Garcia DD, Shtein RM, Musch DC, Elner VM. Herpes simplex virus keratitis: histopathologic neovascularization and corneal allograft failure. Cornea. Oct 2009;28(9):963-965
80. Lomholt JA, Baggesen K, Ehlers N. Recurrence and rejection rates following corneal transplantation for herpes simplex keratitis. Acta Ophthalmol Scand. Feb 1995;73(1):29-32
81. Sottile J. Regulation of angiogenesis by extracellular matrix. Biochim Biophys Acta. Mar 4 2004;1654(1):13-22 (Pubitemid 38230928)
82. Lee S, Zheng M, Kim B, Rouse BT. Role of matrix metalloproteinase- 9 in angiogenesis caused by ocular infection with herpes simplex virus. J Clin Invest. Oct 2002;110(8):1105-1111 (Pubitemid 35215891)
83. Biswas PS, Banerjee K, Kinchington PR, Rouse BT. Involvement of IL-6 in the paracrine production of VEGF in ocular HSV-1 infection. Exp Eye Res. Jan 2006;82(1):46-54 (Pubitemid 43063396)
84. Biswas PS, Banerjee K, Zheng M, Rouse BT. Counteracting corneal immunoinflammatory lesion with interleukin- 1 receptor antagonist protein. J Leukoc Biol. Oct 2004;76(4):868-875 (Pubitemid 39313724)
85. Klinman DM, Zheng M, Gierynska M, Rouse BT. DNA containing bioactive CpG motifs promote angiogenesis. Drug News Perspect. Jul 2002;15(6):358-363
86. Choudhary A, Hiscott P, Hart CA, Kaye SB, Batterbury M, Grierson I. Suppression of thrombospondin 1 and 2 production by herpes simplex virus 1 infection in cultured keratocytes. Mol Vis. Mar 2 2005;11:163-168 (Pubitemid 41358296)
87. Kaye S, Choudhary A. Herpes simplex keratitis. Prog Retin Eye Res. Jul 2006;25(4):355-380 (Pubitemid 44041113)
88. Zhang J, Wu XY, Yu FS. Inflammatory responses of corneal epithelial cells to Pseudomonas aeruginosa infection. Curr Eye Res. Jul 2005;30(7):527-534 (Pubitemid 41113554)
89. Xue ML, Thakur A, Willcox M. Macrophage inflammatory protein-2 and vascular endothelial growth factor regulate corneal neovascularization induced by infection with Pseudomonas aeruginosa in mice. Immunol Cell Biol. Aug 2002;80(4):323-327 (Pubitemid 34784615)
90. Dana MR, Streilein JW. Loss and restoration of immune privilege in eyes with corneal neovascularization. Invest Ophthalmol Vis Sci. Nov 1996;37(12):2485-2494 (Pubitemid 26391286)
91. Dana MR, Schaumberg DA, Kowal VO, et al. Corneal neovascularization after penetrating keratoplasty. Cornea. Nov 1995;14(6):604-609
92. The collaborative corneal transplantation studies (CCTS). Effectiveness of histocompatibility matching in highrisk corneal transplantation. The Collaborative Corneal Transplantation Studies Research Group. Arch Ophthalmol. Oct 1992;110(10):1392-1403
93. Streilein JW. Immunobiology and immunopathology of corneal transplantation. Chem Immunol. 1999;73:186-206 (Pubitemid 29488120)
94. Cursiefen C, Cao J, Chen L, et al. Inhibition of hemangiogenesis and lymphangiogenesis after normal-risk corneal transplantation by neutralizing VEGF promotes graft survival. Invest Ophthalmol Vis Sci. Aug 2004;45(8):2666-2673 (Pubitemid 38998863)
95. Paque J, Poirier RH. Corneal allograft reaction and its relationship to suture site neovascularization. Ophthalmic Surg. Aug 1977;8(4):71-74 (Pubitemid 8182657)
96. Salthouse TN, Matlaga BF, Wykoff MH. Comparative tissue response to six suture materials in rabbit cornea, sclera, and ocular muscle. Am J Ophthalmol. Aug 1977;84(2):224-233 (Pubitemid 8168892)
97. Moore TE, Jr., Aronson SB. Suture reaction in the human cornea. Arch Ophthalmol. Nov 1969;82(5):575-579
98. Zhu S, Dekaris I, Duncker G, Dana MR. Early expression of proinflammatory cytokines interleukin-1 and tumor necrosis factor-alpha after corneal transplantation. J Interferon Cytokine Res. Jun 1999;19(6):661-669 (Pubitemid 29331320)
99. Dana R. Comparison of topical interleukin-1 vs tumor necrosis factor-alpha blockade with corticosteroid therapy on murine corneal inflammation, neovascularization, and transplant survival (an American Ophthalmological Society thesis). Trans Am Ophthalmol Soc. 2007;105:330-343
100. Dastjerdi MH, Saban DR, Okanobo A, et al. Effects of topical and subconjunctival bevacizumab in high-risk corneal transplant survival. Invest Ophthalmol Vis Sci. May 2010;51(5):2411-2417
101. Wong AL, Weissman BA, Mondino BJ. Bilateral corneal neovascularization and opacification associated with unmonitored contact lens wear. Am J Ophthalmol. Nov 2003;136(5):957-958 (Pubitemid 37330060)
102. Weinberg RJ. Deep corneal vascularization caused by aphakic soft contact lens wear. Am J Ophthalmol. Jan 1977;83(1):121-122 (Pubitemid 8025668)
103. Nirankari VS, Karesh J, Lakhanpal V, Richards RD. Deep stromal vascularization associated with cosmetic, daily-wear contact lenses. Arch Ophthalmol. Jan 1983;101(1):46-47 (Pubitemid 13167167)
104. Polse KA, Brand RJ, Cohen SR, Guillon M. Hypoxic effects on corneal morphology and function. Invest Ophthalmol Vis Sci. Aug 1990;31(8):1542-1554 (Pubitemid 20265961)
105. Lin MC, Polse KA. Hypoxia, overnight wear, and tear stagnation effects on the corneal epithelium: Data and proposed model. Eye Contact Lens. Nov 2007;33(6 Pt 2):378-381; discussion 382 (Pubitemid 350059555)
106. Liesegang TJ. Physiologic changes of the cornea with contact lens wear. CLAO J. Jan 2002;28(1):12-27 (Pubitemid 34145987)
107. Bonanno JA, Polse KA. Corneal acidosis during contact lens wear: Effects of hypoxia and CO2. Invest Ophthalmol Vis Sci. Sep 1987;28(9):1514-1520 (Pubitemid 17147781)
108. Ang JH, Efron N. Corneal hypoxia and hypercapnia during contact lens wear. Optom Vis Sci. Jul 1990;67(7):512-521
109. Constant JS, Feng JJ, Zabel DD, et al. Lactate elicits vascular endothelial growth factor from macrophages: A possible alternative to hypoxia. Wound Repair Regen. Sep-Oct 2000;8(5):353-360
110. Chen R, Liliental JE, Kowalski PE, Lu Q, Cohen SN. Regulation of transcription of hypoxia-inducible factor-1- alpha (HIF-1alpha) by heat shock factors HSF2 and HSF4. Oncogene. Jan 24 2011
111. Sasaki H, Ray PS, Zhu L, Galang N, Maulik N. Oxidative stress due to hypoxia/reoxygenation induces angiogenic factor VEGF in adult rat myocardium: possible role of NFkappaB. Toxicology. Nov 30 2000;155(1-3):27-35 (Pubitemid 32056311)
112. Hata Y, Nakagawa K, Ishibashi T, Inomata H, Ueno H, Sueishi K. Hypoxia-induced expression of vascular endothelial growth factor by retinal glial cells promotes in vitro angiogenesis. Virchows Arch. 1995;426(5):479-486
113. Forsythe JA, Jiang BH, Iyer NV, et al. Activation of vascular endothelial growth factor gene transcription by hypoxiainducible factor 1. Mol Cell Biol. Sep 1996;16(9):4604-4613 (Pubitemid 26272112)
114. Conners MS, Stoltz RA, Davis KL, et al. A closed eye contact lens model of corneal inflammation. Part 2: Inhibition of cytochrome P450 arachidonic acid metabolism alleviates inflammatory sequelae. Invest Ophthalmol Vis Sci. Apr 1995;36(5):841-850
115. Davis KL, Conners MS, Dunn MW, Schwartzman ML. Induction of corneal epithelial cytochrome P-450 arachidonate metabolism by contact lens wear. Invest Ophthalmol Vis Sci. Feb 1992;33(2):291-297
116. Conners MS, Stoltz RA, Webb SC, et al. A closed eye contact lens model of corneal inflammation. Part 1: Increased synthesis of cytochrome P450 arachidonic acid metabolites. Invest Ophthalmol Vis Sci. Apr 1995;36(5):828-840
117. Masferrer JL, Murphy RC, Pagano PJ, Dunn MW, Laniado- Schwartzman M. Ocular effects of a novel cytochrome P-450- dependent arachidonic acid metabolite. Invest Ophthalmol Vis Sci. Mar 1989;30(3):454-460 (Pubitemid 19100674)
118. Stoltz RA, Conners MS, Gerritsen ME, Abraham NG, Laniado-Schwartzman M. Direct stimulation of limbal microvessel endothelial cell proliferation and capillary formation in vitro by a corneal-derived eicosanoid. Am J Pathol. Jan 1996;148(1):129-139 (Pubitemid 26019651)